Last $1.65 USD
Change Today -0.05 / -2.94%
Volume 118.3K
ATOS On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 07/10/14 All times are local (Market data is delayed by at least 15 minutes).

atossa genetics inc (ATOS) Snapshot

Open
$1.70
Previous Close
$1.70
Day High
$1.70
Day Low
$1.65
52 Week High
09/18/13 - $7.75
52 Week Low
04/15/14 - $1.15
Market Cap
38.4M
Average Volume 10 Days
170.9K
EPS TTM
--
Shares Outstanding
23.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ATOSSA GENETICS INC (ATOS)

Related News

No related news articles were found.

atossa genetics inc (ATOS) Related Businessweek News

No Related Businessweek News Found

atossa genetics inc (ATOS) Details

Atossa Genetics, Inc. operates as a healthcare company that focuses on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer in the United States. Its diagnostic tests include the ForeCYTE Breast Health Test, which provides personalized information about the 10-year and lifetime risk of breast cancer for women between ages 18 and 65; and the ArgusCYTE Breast Health Test that offers information to help inform breast cancer treatment options and to help monitor potential recurrence. The company also intends to offers FullCYTE Breast Health Test, which is in development to assess the individual breast ducts for pre-cancerous changes in women; and NextCYTE Breast Cancer Test that is in the prevalidation phase to profile breast cancer specimens for prediction of treatment outcomes and distant recurrence in women newly diagnosed with breast cancer. Atossa Genetics, Inc. was founded in 2009 and is headquartered in Seattle, Washington.

16 Employees
Last Reported Date: 03/27/14
Founded in 2009

atossa genetics inc (ATOS) Top Compensated Officers

Chairman, Chief Executive Officer, President ...
Total Annual Compensation: $259.3K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $225.0K
Chief Scientific Officer and Director
Total Annual Compensation: $207.4K
Compensation as of Fiscal Year 2013.

atossa genetics inc (ATOS) Key Developments

Atossa Genetics, Inc. Replaces KCCW Accountancy Corp. with BDO USA, LLP as Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2014

The Audit Committee of the board of directors of Atossa Genetics Inc. recently conducted a competitive process to determine the company’s independent registered public accounting firm for the fiscal year ending December 31, 2014. As a result of this process, on June 24, 2014, the company approved the engagement of BDO USA, LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2014. On the same date, the company dismissed KCCW Accountancy Corp. as the company’s independent registered public accounting firm, effective immediately. The committee approved these changes in the company’s independent registered public accounting firm on June 24, 2014.

Atossa Genetics, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-20-2014 01:10 PM

Atossa Genetics, Inc. Presents at Washington Biotechnology & Biomedical Association 14th Annual Life Science Innovation Northwest 2014, Jun-20-2014 01:10 PM. Venue: Washington State Convention Center, Seattle, Washington, United States.

Atossa Genetics Hires John E. Sawyer as Senior Vice President of Global Regulatory Affairs and Quality Assurance

Atossa Genetics Inc. announced it has hired John E. Sawyer as Senior Vice President of Global Regulatory Affairs and Quality Assurance effective June 1, 2014. For the past fifteen months, Mr. Sawyer has played a key advisory role as Atossa's Regulatory Affairs/Quality Assurance consultant, advising Atossa's Executive Management Team on Atossa's quality management systems and regulatory affairs activities with the U.S. Food and Drug Administration. Beginning now, Mr. Sawyer will be responsible for establishing and executing the regulatory strategy for Atossa for both the U.S. and international markets, ensuring that the quality management system appropriately addresses all U.S. and International quality standards while maintaining positive and pro-active interactions with U.S. and international regulatory authorities. Mr. Sawyer brings 25 years of Regulatory Affairs and Quality Assurance experience in medical devices in both U.S. and international markets, including regulatory standards, product life-cycle management, risk management, R&D, clinical studies, post-market surveillance, supply chain management and acquisitions. In addition, Mr. Sawyer has established quality management systems based on the FDA Quality System Regulation, ISO-13485, Canadian Medical Device Conformity Assessment System and the European Medical Device Directive along with quality management system remediation activities to return organizations into compliance with these standards. Mr. Sawyer replaces Ben Chen, the former head of regulatory and quality assurance for Atossa.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ATOS:US $1.65 USD -0.05

ATOS Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biocept Inc $6.42 USD +0.47
Illumina Inc $173.99 USD -1.24
View Industry Companies
 

Industry Analysis

ATOS

Industry Average

Valuation ATOS Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 87.6x
Price/Book 1.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 52.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ATOSSA GENETICS INC, please visit www.atossagenetics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.